Preclinical
Filter News
Found 9,591 articles
-
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
2/15/2024
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol in non-human primates.
-
Preclinical Data on PIV5-based Intranasal Vaccine Against Lyme Disease Demonstrates Durable Immune Response
2/15/2024
CyanVac LLC and Immuno Technologies, Inc. announced the publication in NPJ Vaccines of preclinical data showing that mice inoculated with a PIV5-based intranasal vaccine against Lyme disease demonstrated long-lasting neutralizing antibody responses and long-term protection of up to 15 months against multiple strains of Borrelia burgdorferi, the causative agent of Lyme disease.
-
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
2/13/2024
Satellos Bioscience Inc. announced positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy.
-
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
2/13/2024
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases.
-
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
2/13/2024
Sana Biotechnology, Inc. announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.”
-
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy
2/12/2024
Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new clinical and preclinical results from the nadunolimab (CAN04) program, providing a promising starting point for additional future opportunities.
-
Polaroid Therapeutics completes pre-clinical milestones in the development of superior antimicrobial technology for acute and chronic wounds
2/11/2024
Polaroid Therapeutics, a Swiss-based biotech start-up, is developing advanced antimicrobial therapies to enhance patient outcomes worldwide.
-
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
2/7/2024
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications.
-
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
2/6/2024
Scholar Rock today announced new preclinical data showing the potential of SRK-439 to preserve lean mass and improve metabolic health as part of healthy weight loss.
-
AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference
2/6/2024
AlzeCure Pharma AB announced that an abstract on preclinical data with its lead drug candidate NeuroRestore ACD856 has been accepted for a poster presentation at AD/PD 2024, which will be held in Lisbon on March 5-9.
-
Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth
2/6/2024
Stemson Therapeutics announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials.
-
Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems
2/6/2024
Bruker Corporation announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.
-
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
2/5/2024
Vaxart, Inc. announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s.
-
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
2/2/2024
Synlogic, Inc. (Nasdaq: SYBX) announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).
-
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
2/1/2024
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA.
-
Drug discovery requires complex and multi-faceted decisions to justify billion-dollar investments that will take years to realize.
-
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
1/29/2024
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247.
-
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
1/25/2024
Organovo Holdings, Inc. (Nasdaq: ONVO) today announced the presentation of preclinical data related to the company’s FXR314 development program in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis at the Crohn’s and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada.
-
HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data
1/24/2024
HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.
-
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
1/23/2024
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer's disease treatment in a significant manner.